Get the Stockscreener App
1.31
3.15%
0.04
Igm Biosciences Inc stock is traded at $1.31, with a volume of 487.36K.
It is up +3.15% in the last 24 hours and up +1.55% over the past month.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
See More
Previous Close:
$1.27
Open:
$1.29
24h Volume:
487.36K
Relative Volume:
0.86
Market Cap:
$45.59M
Revenue:
$2.91M
Net Income/Loss:
$-220.40M
P/E Ratio:
-0.3599
EPS:
-3.64
Net Cash Flow:
$-176.15M
1W Performance:
+3.15%
1M Performance:
+1.55%
6M Performance:
-13.25%
1Y Performance:
-86.47%
1-Day Range:
$1.28
$1.33
1-Week Range:
$1.25
$1.33
52-Week Range:
$0.92
$22.50
Igm Biosciences Inc Stock (IGMS) Company Profile
Name
Igm Biosciences Inc
Sector
Industry
Phone
650-965-7873
Address
325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW
Compare IGMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IGMS
Igm Biosciences Inc
|
1.31 | 76.44M | 2.91M | -220.40M | -176.15M | -3.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Igm Biosciences Inc Stock (IGMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-10-25 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-10-25 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-10-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-10-25 | Downgrade | Stifel | Buy → Hold |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-01-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-24 | Downgrade | Truist | Buy → Hold |
| Feb-09-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-07-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-09-22 | Resumed | Jefferies | Buy |
| Oct-17-22 | Initiated | JP Morgan | Neutral |
| Aug-29-22 | Initiated | BofA Securities | Buy |
| Dec-13-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-05-21 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-26-21 | Initiated | Morgan Stanley | Overweight |
| Jan-29-21 | Initiated | RBC Capital Mkts | Outperform |
| Jan-19-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-22-20 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-17-20 | Initiated | Robert W. Baird | Outperform |
| Jul-01-20 | Initiated | H.C. Wainwright | Buy |
| May-28-20 | Initiated | SunTrust | Buy |
| Apr-22-20 | Initiated | Wedbush | Outperform |
| Oct-14-19 | Initiated | Guggenheim | Buy |
| Oct-14-19 | Initiated | Jefferies | Buy |
| Oct-14-19 | Initiated | Piper Jaffray | Overweight |
| Oct-14-19 | Initiated | Stifel | Buy |
View All
Igm Biosciences Inc Stock (IGMS) Latest News
Chart based exit strategy for IGM Biosciences Inc.High Probability Trade Outcome Prediction - Newser
Sentiment Tools Show Shift in Trader Mood on IGM Biosciences Inc.Earnings Play Trade Plan With Alerts Shared - metal.it
What catalysts could drive IGM Biosciences Inc. stock higher in 2025Pre Market Trend Scanner With High Returns - jammulinksnews.com
Is IGM Biosciences Inc. a candidate for recovery playScalable Strategy with Chart Confirmation - Newser
Custom watchlist performance reports with IGM Biosciences Inc.High Return Trade Roadmap with Setup Filters - Newser
IGM Biosciences Q2 2025 Earnings Report: Persistent Losses Amid Weak Earnings Beat Performance - AInvest
IGM Biosciences, Inc. (IGMS) Q2 Earnings and Revenues Surpass Estimates - sharewise.com
IGM Biosciences Surpasses Earnings and Revenue Estimates in Q2, Shares Down 79.4% YTD - AInvest
How does IGM Biosciences Inc. generate profit in a changing economyFree Stock Alerts For Every Investor - jammulinksnews.com
IGM Biosciences Q2 2025 Earnings Miss: A Harbinger of Persistent Pressure - AInvest
IGM Biosciences Inc. stock daily chart insightsAlpha Stock Picks with Chart Confirmation - Newser
Competitive Positioning of IGM Biosciences Inc.: Is It Leading or LaggingFree Oversold Bounce Stock Play Ideas - Newser
Why IGM Biosciences Inc. stock attracts strong analyst attentionFree Consistent Income Focused Trade List - Newser
Multi factor analysis applied to IGM Biosciences Inc.Predictable Return Plan with Entry Guidance - Newser
Key metrics from IGM Biosciences Inc.’s quarterly dataShort-Term Trade Setup with Forecast Insight - Newser
Volume spikes in IGM Biosciences Inc. stock – what they meanFree Low Risk Picks for Daily Trading - Newser
Predicting IGM Biosciences Inc. trend using moving averagesDeep Learning Stock Forecast for Investors - Newser
Mary Beth Harler Sells 14,501 Shares of IGM Biosciences, Inc. (NASDAQ:IGMS) Stock - MarketBeat
What makes IGM Biosciences Inc. stock price move sharplyFree Accurate Technical Trend Reversal Picks - Newser
IGM Biosciences, Inc. (NASDAQ:IGMS) CFO Misbah Tahir Sells 8,741 Shares - MarketBeat
Will IGM Biosciences Inc. Recover After Recent DeclineCapital Growth With Controlled Risk Picks Suggested - metal.it
Is IGM Biosciences Inc. a growth stock or a value stockCapitalize on market trends with confidence - jammulinksnews.com
How does IGM Biosciences Inc. compare to its industry peersExponential return rates - jammulinksnews.com
Order flow analysis tools used on IGM Biosciences Inc. Free Trade Setups With Clear Risk Limits - Newser
How strong is IGM Biosciences Inc. company’s balance sheetBuild wealth with long-term growth strategies - jammulinksnews.com
What are analysts’ price targets for IGM Biosciences Inc. in the next 12 monthsRapid capital growth - jammulinksnews.com
What is the risk reward ratio of investing in IGM Biosciences Inc. stockBuild wealth steadily with smart stock selection - jammulinksnews.com
Published on: 2025-07-28 03:57:27 - jammulinksnews.com
Is it the right time to buy IGM Biosciences Inc. stockFree Stock Market Forecast Reports - jammulinksnews.com
How IGM Biosciences Inc. stock performs during market volatilityStrategic High Profit Opportunities - Newser
Igm Biosciences CFO Tahir sells $11k in stock By Investing.com - Investing.com Canada
Igm Biosciences CEO Harler sells $18k in shares By Investing.com - Investing.com Canada
Igm Biosciences CBO Decker sells $5611 in stock By Investing.com - Investing.com Canada
IGM Biosciences Executives Sell Shares to Cover Tax Obligations - TradingView
What drives IGM Biosciences Inc. stock priceExceptional trading performance - PrintWeekIndia
What analysts say about IGM Biosciences Inc. stockExtraordinary earning power - PrintWeekIndia
Will IGM Biosciences Inc. stock benefit from interest rate changesHigh-profit stock alerts - jammulinksnews.com
Fierce Biotech Layoff Tracker 2025: Rocket ejects 30% of staffers; Flagship's Tessera and Generate Bio trim teams - Fierce Biotech
IGM Biosciences, Inc. (NASDAQ:IGMS) Receives $5.50 Consensus Price Target from Brokerages - MarketBeat
Igm Biosciences Inc Stock (IGMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):